Table 1.

Baseline patient demographics based on 6 patient groups undergoing cessation of anti-platelet therapy, with a further group receiving uninterrupted DAPT.

	Entire cohort	Permanent d/c Aspirin + Clopidogrel	Temporary d/c Aspirin + Clopidogrel	Permanent d/c Aspirin	Temporary d/c Aspirin	Permanent d/c Clopidogrel	Temporary d/c Clopidogrel	Uninterrupted DAPT	p value
N	5681	118	331	187	54	713	208	4070
Age (years)	66 ± 11	68 ± 12	66 ± 10	69 ± 11	68 ± 11	67 ± 11	66 ± 11	65 ± 12	<0.0001
Male gender (%)	67	69	63	61	56	62	72	68	0.032
Hypertension (%)	88	86	88	86	90	87	89	84	0.021
Diabetes (%)	38	39	32	30	37	27	35	41	<0.0001
Hyperlipidemia (%)	88	86	90	86	89	84	90	89	0.0012
Current smoker (%)	18	22	17	17	15	15	18	15	0.43
Previous CABG (%)	15	14	15	9	13	10	15	16	0.0041
Chronic renal impairment (%)	11	11	11	15	6	7	10	11	0.012
LVEF (%)	54 ± 9	54 ± 10	54 ± 10	53 ± 11	54 ± 10	55 ± 8	54 ± 10	54 ± 10	0.22
Receiving Coumadin (%)	5	13	4	12	9	6	3	4	<0.0001
Presenting syndrome									0.19
Stable angina (%)	57	64	63	57	58	61	56	56
Unstable angina (%)	34	28	30	30	36	30	36	35
AMI (%)	9	8	7	13	6	9	8	9

P value represents results of Pearson’s chi-square test or ANOVA for overall differences among groups. d/c discontinuation; LVEF = left ventricular ejection fraction.